Login / Signup

Patients transitioning from non-pegylated to pegylated interferon beta-1a have a low risk of new flu-like symptoms: ALLOW phase 3b trial results.

Robert T NaismithBarry HendinSibyl WrayDeRen HuangFiorenza GaudenziQunming DongBjørn SperlingMonica MannBrian Werneburg
Published in: Multiple sclerosis journal - experimental, translational and clinical (2019)
Most patients who switched from non-pegylated interferon to peginterferon beta-1a did not experience new/worsening flu-like symptoms. Flu-like symptom duration per injection increased, but the cumulative duration significantly decreased. These data may inform flu-like symptom management guidance.
Keyphrases